Weil Advises Allergan on Antitrust Issues in $160 Billion Merger with Pfizer

Thursday, December 3, 2015 - 15:04

Weil’s Antitrust team is advising Allergan plc, a global pharmaceutical company in its definitive merger agreement with Pfizer Inc., a global biopharmaceutical company, in a deal valued at approximately $160 billion. Under the terms of the proposed transaction, the businesses of Pfizer and Allergan will be combined under Allergan plc, which will be renamed “Pfizer plc.”

Weil has advised Allergan in numerous other prominent Antitrust matters including:

  • Allergan’s $40.5 billion sale of its Global Generic Pharmaceuticals Business (July 27, 2015)
  • Allergan’s approximately $2.1 billion acquisition of KYTHERA Biopharmaceuticals Inc (June 18, 2015)
  • Actavis plc’s approximately $70.5 billion acquisition of Allergan (November 17, 2014)

Weil’s Antitrust team includes partners Steven Newborn and Ann Malester and associates Brianne Kucerik, Megan Granger, Joy Dineo and Cecile Farmer (not yet admitted to practice)